Leerink on Structure Therapeutics (GPCR): 'Oral GLP-1 Achieves Best-In-Class Weight Loss'
Tweet Send to a Friend
Leerink Partners analyst David Risinger reiterated an Outperform rating and $90.00 price target on Structure Therapeutics (NASDAQ: GPCR).The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
